These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

584 related items for PubMed ID: 27366312

  • 1. New Developments in Chronic Myeloid Leukemia: Implications for Therapy.
    Tabarestani S, Movafagh A.
    Iran J Cancer Prev; 2016 Feb; 9(1):e3961. PubMed ID: 27366312
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions.
    Osman AEG, Deininger MW.
    Blood Rev; 2021 Sep; 49():100825. PubMed ID: 33773846
    [Abstract] [Full Text] [Related]

  • 5. Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia.
    Moore FR, Yang F, Press RD.
    Methods Mol Biol; 2013 Sep; 999():25-39. PubMed ID: 23666688
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Reactive oxygen species in BCR-ABL1-expressing cells - relevance to chronic myeloid leukemia.
    Antoszewska-Smith J, Pawlowska E, Blasiak J.
    Acta Biochim Pol; 2017 Sep; 64(1):1-10. PubMed ID: 27904889
    [Abstract] [Full Text] [Related]

  • 8. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
    Huang T, Fu Y, Wang S, Xu M, Yin X, Zhou M, Wang X, Chen C.
    Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
    [Abstract] [Full Text] [Related]

  • 9. Characterization of cancer stem cells in chronic myeloid leukaemia.
    Jørgensen HG, Holyoake TL.
    Biochem Soc Trans; 2007 Nov; 35(Pt 5):1347-51. PubMed ID: 17956348
    [Abstract] [Full Text] [Related]

  • 10. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
    Pietarinen PO, Eide CA, Ayuda-Durán P, Potdar S, Kuusanmäki H, Andersson EI, Mpindi JP, Pemovska T, Kontro M, Heckman CA, Kallioniemi O, Wennerberg K, Hjorth-Hansen H, Druker BJ, Enserink JM, Tyner JW, Mustjoki S, Porkka K.
    Oncotarget; 2017 Apr 04; 8(14):22606-22615. PubMed ID: 28186983
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia.
    Kaehler M, Cascorbi I.
    Front Pharmacol; 2021 Apr 04; 12():696960. PubMed ID: 34262462
    [Abstract] [Full Text] [Related]

  • 13. A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
    Wagle M, Eiring AM, Wongchenko M, Lu S, Guan Y, Wang Y, Lackner M, Amler L, Hampton G, Deininger MW, O'Hare T, Yan Y.
    Leukemia; 2016 Jul 04; 30(7):1493-501. PubMed ID: 27044711
    [Abstract] [Full Text] [Related]

  • 14. Clinical Insights into Structure, Regulation, and Targeting of ABL Kinases in Human Leukemia.
    Wu A, Liu X, Fruhstorfer C, Jiang X.
    Int J Mol Sci; 2024 Mar 14; 25(6):. PubMed ID: 38542279
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Simultaneous Inhibition of BCR-ABL1 Tyrosine Kinase and PAK1/2 Serine/Threonine Kinase Exerts Synergistic Effect against Chronic Myeloid Leukemia Cells.
    Flis S, Bratek E, Chojnacki T, Piskorek M, Skorski T.
    Cancers (Basel); 2019 Oct 12; 11(10):. PubMed ID: 31614827
    [Abstract] [Full Text] [Related]

  • 17. Assessing Measurable Residual Disease in Chronic Myeloid Leukemia. BCR-ABL1 IS in the Avant-Garde of Molecular Hematology.
    Moisoiu V, Teodorescu P, Parajdi L, Pasca S, Zdrenghea M, Dima D, Precup R, Tomuleasa C, Soverini S.
    Front Oncol; 2019 Oct 12; 9():863. PubMed ID: 31608223
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia.
    Soverini S, de Benedittis C, Mancini M, Martinelli G.
    Clin Lymphoma Myeloma Leuk; 2015 Jun 12; 15 Suppl():S120-8. PubMed ID: 26297264
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.